Top

Published in:

01-12-2018 | Original Article

Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2

Authors: Prasanth S. Ariyannur, Narendranath Vikkath, Ashok B. Pillai

Published in: Cancer Microenvironment | Issue 2-3/2018

Abstract

Neurofibromatosis type 2 (NF-2) is associated with mainly three types of recurrent benign tumors restricted to the central nervous system: schwannoma, meningioma and ependymoma. The absence of the protein NF2/Merlin causes an uninterrupted cell proliferation cascade originating from an abnormal interaction between an extracellular mucopolysaccharide, hyaluronan (HA), and schwann cell surface CD44 receptor, which has been identified as one of the central causative factors for schwannoma. Most tumors in NF-2 have a predilection to originate from either arachnoid cap cells or schwann cells of the cisternal portion of nerve rootlets that share a continuous exposure to cerebrospinal fluid (CSF). We hypothesize that the CSF HA may play a role in tumorigenesis in NF-2. In a prospective analysis over a period of one year, the levels of medium to low molecular weight HA (LMW HA) was estimated in the CSF of three subjects with central schwannomas and compared against that of age-sex matched controls, using Cetyltrimethylammonium bromide coupled turbidimetric assay and found to be seventeen-fold higher in the schwannoma subjects compared to the controls. HA was observed to be actively secreted by cultured schwannoma cells isolated from tumor tissues commensurate with their proliferation rate. On cell viability index analysis to compare the cell proliferation of astrocytoma cells with LMW HA vs. oligomeric HA (OHA), we found a decrease in cell proliferation of up to 30% with OHA. The study provides initial evidence that CSF HA may have a central role in the tumorigenesis of schwannoma in NF-2.

Available only for authorised users

Rouleau G, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515–521. https://doi.org/10.1038/363515a0 CrossRefPubMed

Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Diseases 4:16. https://doi.org/10.1186/1750-1172-4-16 CrossRef

Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher tncidence than previously thought. Otol Neurotol 26(1):93–97CrossRef

Baser ME, Contributors to the International NFMD (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27(4):297–306. https://doi.org/10.1002/humu.20317 CrossRefPubMed

Bianchi A, Hara T, Ramesh V, Gao J, Klein-Szanto A, Morin F, Menon A, Trofatter J, Gusella J, Seizinger B (1994) Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 6(2):185–192. https://doi.org/10.1038/ng0294-185 CrossRefPubMed

Stamenkovic I, Yu Q (2010) Merlin, a “magic” linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11(6):471–484CrossRef

Schroeder RD, Angelo LS, Kurzrock R (2014) NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget 5(1):67–77. https://doi.org/10.18632/oncotarget.1557 CrossRefPubMed

Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S (1994) ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126(2):391–401. https://doi.org/10.1083/jcb.126.2.391 CrossRefPubMed

Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S, Tsukita S (1998) Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140(4):885–895. https://doi.org/10.1083/jcb.140.4.885 CrossRefPubMedPubMedCentral

10.

Curto M, McClatchey A (2008) Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 98(2):256–262. https://doi.org/10.1038/sj.bjc.6604002 CrossRefPubMed

11.

McClatchey A, Giovannini M (2005) Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev 19(19):2265–2277. https://doi.org/10.1101/gad.1335605 CrossRefPubMed

12.

Morrison H, Sherman L, Legg J, Banine F, Isacke C, Haipek C, Gutmann D, Ponta H, Herrlich P (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15(8):968–980. https://doi.org/10.1101/gad.189601 CrossRefPubMedPubMedCentral

13.

Ponta H, Sherman L, Herrlich P (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45. https://doi.org/10.1038/nrm1004 CrossRefPubMed

14.

Joy RA, Vikkath N, Ariyannur PS (2018) Metabolism and mechanisms of action of hyaluronan in human biology. Drug Metabolism and Personalized Therapy 33(1):15–32. https://doi.org/10.1515/dmpt-2017-0031 CrossRefPubMed

15.

James M, Lelke J, Maccollin M, Plotkin S, Stemmer-Rachamimov A, Ramesh V, Gusella J (2008) Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis 29(2):278–292. https://doi.org/10.1016/j.nbd.2007.09.002 CrossRefPubMed

16.

Toole B (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4(7):528–539. https://doi.org/10.1038/nrc1391 CrossRefPubMed

17.

Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11(4):254–267. https://doi.org/10.1038/nrc3023 CrossRefPubMed

18.

Toole BP (2001) Hyaluronan in morphogenesis. Semin Cell Dev Biol 12(2):79–87. https://doi.org/10.1006/scdb.2000.0244 CrossRefPubMed

19.

Stern R (2009) Hyaluronan in cancer biology. Hyaluronan in Cancer Biology, vol 1, 1st edn. Academic Press, Elsevier Inc, San Diego

20.

Koochekpour S, Pilkington G, Merzak A (1995) Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 63(3):450–454. https://doi.org/10.1002/ijc.2910630325 CrossRefPubMed

21.

Weaver V, Gilbert P (2004) Watch thy neighbor: cancer is a communal affair. J Cell Sci 117(Pt 8):1287–1290. https://doi.org/10.1242/jcs.01137 CrossRefPubMed

22.

Bourguignon L, Zhu H, Zhou B, Diedrich F, Singleton P, Hung M (2001) Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 276(52):48679–48692. https://doi.org/10.1074/jbc.M106759200 CrossRefPubMed

23.

Misra S, Heldin P, Hascall V, Karamanos N, Skandalis S, Markwald R, Ghatak S (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278(9):1429–1443. https://doi.org/10.1111/j.1742-4658.2011.08071.x CrossRefPubMedPubMedCentral

24.

Turley EA, Noble PW, Bourguignon LY (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277(7):4589–4592. https://doi.org/10.1074/jbc.R100038200 CrossRefPubMed

25.

Chen Y-H, Wang Q (2009) Establishment of CTAB Turbidimetric method to determine hyaluronic acid content in fermentation broth. Carbohydr Polym 78(1):178–181. https://doi.org/10.1016/j.carbpol.2009.04.037 CrossRef

26.

Song J-M, Im J-H, Kang J-H, Kang D-J (2009) A simple method for hyaluronic acid quantification in culture broth. Carbohydr Polym 78(3):633–634. https://doi.org/10.1016/j.carbpol.2009.04.033 CrossRef

27.

Di Ferrante N (1956) Turbidimetric measurement of acid mucopolysaccharides and hyaluronidase activity. J Biol Chem 220(1):303–306

28.

Kaewkhaw R, Scutt AM, Haycock JW (2012) Integrated culture and purification of rat Schwann cells from freshly isolated adult tissue. Nat Protoc 7(11):1996–2004. https://doi.org/10.1038/nprot.2012.118 CrossRefPubMed

29.

Ward J, Huang L, Guo H, Ghatak S, Toole B (2003) Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol 162(5):1403–1409. https://doi.org/10.1016/s0002-9440(10)64273-3 CrossRefPubMedPubMedCentral

30.

Boncler M, Rozalski M, Krajewska U, Podsedek A, Watala C (2014) Comparison of PrestoBlue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells. J Pharmacol Toxicol Methods 69(1):9–16. https://doi.org/10.1016/j.vascn.2013.09.003 CrossRefPubMed

31.

Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DGR (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genetics In Medicine 13:576. https://doi.org/10.1097/GIM.0b013e318211faa9 CrossRefPubMed

32.

Baggenstoss BA, Weigel PH (2006) Size exclusion chromatography-multiangle laser light scattering analysis of hyaluronan size distributions made by membrane-bound hyaluronan synthase. Anal Biochem 352(2):243–251. https://doi.org/10.1016/j.ab.2006.01.019 CrossRefPubMedPubMedCentral

33.

Laurent UBG, Laurent TC, Hellsing LK, Persson L, Hartman M, Lilja K (1996) Hyaluronan in human cerebrospinal fluid. Acta Neurol Scand 94:194–206. https://doi.org/10.1111/j.1600-0404.1996.tb07052.x CrossRefPubMed

34.

Laurent UB, Tengblad A (1980) Determination of hyaluronate in biological samples by a specific radioassay technique. Anal Biochem 109(2):386–394CrossRef

35.

Sherman L, Skroch-Angel P, Moll J, Schwechheimer K, Ponta H, Herrlich P, Hofmann M (1995) Schwann cell tumors express characteristic patterns of CD44 splice variants. J Neuro-Oncol 26(3):171–184. https://doi.org/10.1007/bf01052620 CrossRef

36.

Sherman L, Xu H, Geist R, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, Gutmann D (1997) Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15(20):2505–2509. https://doi.org/10.1038/sj.onc.1201418 CrossRefPubMed

37.

Schworer CM, Masker KK, Wood GC, Carey DJ (2003) Microarray analysis of gene expression in proliferating Schwann cells: synergistic response of a specific subset of genes to the mitogenic action of heregulin plus forskolin. J Neurosci Res 73(4):456–464. https://doi.org/10.1002/jnr.10679 CrossRefPubMed

38.

Neff BA, Voss SG, Schmitt WR, Driscoll CL, Link MJ, Beatty CW, Kita H (2012) Inhibition of MEK pathway in vestibular schwannoma cell culture. Laryngoscope 122(10):2269–2278. https://doi.org/10.1002/lary.23472 CrossRefPubMed

39.

Ghatak S, Misra S, Toole B (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013–38020. https://doi.org/10.1074/jbc.M202404200 CrossRefPubMed

40.

Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q (2007) Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26(6):836–850. https://doi.org/10.1038/sj.onc.1209849 CrossRefPubMed

41.

Maharjan AS, Pilling D, Gomer RH (2011) High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS One 6(10):e26078. https://doi.org/10.1371/journal.pone.0026078 CrossRefPubMedPubMedCentral

Title: Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2
Authors: Prasanth S. Ariyannur
Narendranath Vikkath
Ashok B. Pillai
Publication date: 01-12-2018
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 2-3/2018
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-018-0216-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2018

Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma

Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes

Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line

Keynote webinar | Spotlight on antibody–drug conjugates in cancer